Innate Pharma: five abstracts selected for ASCO
One poster will present final data from the TELLOMAK Phase 2 trial in mycosis fungoides, confirming lacutamab's promising clinical activity, while two others will focus on IPH6501 for the treatment of non-Hodgkin's B lymphoma.
Two other posters, presented by partner AstraZeneca, will focus on phase 2 trials with monalizumab in non-operable stage III non-small cell lung cancer and small cell lung cancer.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction